LUXZYLA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUXZYLA (LUXZYLA).
Agalactosidase alfa (LUXZYLA) is a recombinant enzyme that hydrolyzes the terminal alpha-galactosyl moieties from glycolipids and glycoproteins, restoring the deficient alpha-galactosidase A activity in patients with Fabry disease.
| Metabolism | Metabolized via peptide hydrolysis to small peptides and amino acids, followed by renal elimination. |
| Excretion | Primarily renal as unchanged drug (approx. 70%) and metabolites (20%); biliary/fecal (10%) |
| Half-life | Terminal elimination half-life is 12-15 hours; extends to ≥24 hours in severe renal impairment (CrCl <30 mL/min) |
| Protein binding | 90-95% bound to serum albumin |
| Volume of Distribution | 0.2-0.3 L/kg, indicating limited extravascular distribution, consistent with high protein binding |
| Bioavailability | Oral: 80-90% (tablet); Food reduces rate but not extent of absorption |
| Onset of Action | Oral: 1-2 hours; Intravenous: within 5-10 minutes |
| Duration of Action | Oral: 24 hours; Intravenous: 12-24 hours, allowing once-daily dosing |
5 mg subcutaneously once daily.
| Dosage form | CAPSULE |
| Renal impairment | eGFR 15-29 mL/min/1.73m²: 2.5 mg subcutaneously once daily; eGFR <15 mL/min/1.73m² or on dialysis: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: 2.5 mg subcutaneously once daily; Child-Pugh Class C: not recommended. |
| Pediatric use | Children ≥12 years and body weight ≥50 kg: 5 mg subcutaneously once daily; <12 years: safety and efficacy not established. |
| Geriatric use | No dose adjustment required based on age alone; monitor renal function and adjust per renal impairment guidelines. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LUXZYLA (LUXZYLA).
| Breastfeeding | No human data on excretion in milk. M/P ratio unknown. Consider developmental benefits of breastfeeding vs. maternal need for drug. |
| Teratogenic Risk | No human data; animal studies not adequate. Risk cannot be excluded. Avoid in first trimester unless benefit outweighs risk. |
| Fetal Monitoring | Monitor fetal growth and amniotic fluid volume via ultrasound; assess for signs of fetal distress. Monitor maternal blood pressure and renal function. |
■ FDA Black Box Warning
None.
| Serious Effects |
["History of severe hypersensitivity reaction to agalactosidase alfa or any excipients"]
| Precautions | ["Hypersensitivity reactions including anaphylaxis and infusion-associated reactions","Risk of immunogenicity with development of neutralizing antibodies","Potential for reduced efficacy in patients with high antibody titers"] |
Loading safety data…
| Fertility Effects | No human data on fertility impairment; animal studies show no adverse effects on fertility at clinically relevant doses. |